Xiang-Qun (Sean) Xie
Xiang-Qun (Sean) Xie
Dr. Xie got his Pharmacy MD from Second Military Medical University Shanghai in 1982, his PhD in 1993 from University of Connecticut, followed by Biophysics Post-doctoral training at MIT/UCONN, and also obtained his EMBA in 2003. He is a PI of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup (www.CBLigand.org/XieLab) and also Director/PI of NIH NIDA Center of Excellence for Computational Chemogenomics Drug Abuse Research (www.CBLigand.org/CCGS). His research focuses on cloud computing chemogenomics knowledgebased drug design and development for multiple myeloma, osteoporosis and hematopoietic stem cells (4 patents) as well as neurodegenerative diseases and drug abuse research by developing an integrated platform of computational chemogenomics, structural biophysics, HTS bioassay and medicinal chemistry synthesis. He is a charter Member of the NIH BPNS Study Section and ad hoc expert reviewer for United Kingdom MRC MCMB foundation, the Wellcome Trust Fund, the Netherland Organization for Scientific Research Council and the Chinese Natural Science Foundation, etc. He is a guest editor for AAPS Journal, and Associate Editor of BMC Pharmacology and Toxicology. He was honored as “XieHe Lecture Professor” of Chinese Academy of Medical Sciences and Tianjin “1000 scientist” in 2013. He has over 100 publications of peer-reviewed research articles, book chapters, reviews and 4 invention patents.